NewDEL Biotech secures tens of millions in Series A+ follow-on funding, pioneering drug R&D innovation with "DEL+AI" dual-driven approach

NewDEL Biotech recently completed a Series A+ strategic financing round raising tens of millions. This round was led by existing shareholder XtalPi (2228.HK), a Hong Kong-listed company, which provided additional investment. This marks significant capital support secured by NewDEL Biotech within six months, following the earlier investment from XtalPi.

The funds raised will be primarily allocated to advancing the research and enhancement of NewDEL Biotech's integrated "DEL+AI" technology platform, accelerating the layout and clinical development of its innovative drug pipeline, and further improving the efficiency and success rate of early-stage drug discovery.

NewDEL Biotech specializes in the in-depth development and application of DNA-encoded library (DEL) technology, and is dedicated to empowering and advancing innovative drug research and development through its distinct technological capabilities. Its proprietary Live Cell DEL platform enables effective screening of membrane proteins that are challenging to express and purify, not only expanding the range of targets accessible to DEL technology but also offering a screening approach that more closely mimics physiological conditions.

As a pioneer in AI-driven drug research, XtalPi leverages its high-precision drug design platform, which integrates quantum physics, artificial intelligence (AI) algorithms, and automated robotic experimentation. This platform provides the capacity to explore ultra-large chemical spaces and enables rapid molecular optimization, positioning the company at the forefront of the next generation of intelligent drug discovery.

Through this strategic collaboration, the two parties will deepen their cooperation across key research and development stages, including target identification, molecular design and optimization, and preclinical studies. By establishing an integrated R&D workflow that combines "high-throughput DEL screening with AI-enabled analysis and optimization," the partnership aims to overcome the traditional bottlenecks in drug development—such as extended timelines, high costs, and low success rates—and pioneer a new, more efficient and precise paradigm for novel drug discovery.

Currently, the deep integration of AI and biotechnology is leading the global pharmaceutical industry into a new era of intelligent R&D. The partnership between NewDEL Biotech and XtalPi represents not only a synergy of technological innovation but also a high degree of alignment in industrial resources and strategic planning. Moving forward, the two companies will continue to explore the extensive application of DEL and AI across broader disease areas and pipeline development, empowering Chinese innovative pharmaceutical companies to gain greater influence on the global stage.